State of Wyoming’s ADC Therapeutics ADCT Stock Holding History

State of Wyoming’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.11K	Buy	5,713 +3,681	+181%	+$10.7K	﹤0.01%	1845
2026 Q1	$7.62K	Buy	+2,032	New	+$8.01K	﹤0.01%	1734
2025 Q1	–	Sell	-8,267	Closed	-$16.5K	–	1626
2024 Q4	$16.5K	Buy	+8,267	New	+$21.6K	﹤0.01%	1526
2024 Q3	–	Sell	-6,221	Closed	-$19.7K	–	1675
2024 Q2	$19.7K	Buy	+6,221	New	+$24.7K	﹤0.01%	1552
2022 Q2	–	Sell	-2,882	Closed	-$42K	–	1838
2022 Q1	$42K	Buy	2,882 +1,057	+58%	+$16.8K	0.02%	1144
2021 Q4	$37K	Buy	1,825 +276	+18%	+$6.66K	0.02%	1237
2021 Q3	$42K	Sell	1,549 -807	-34%	-$20.7K	0.03%	800
2021 Q2	$57K	Buy	2,356 +1,481	+169%	+$34.4K	0.04%	707
2021 Q1	$21K	Buy	+875	New	+$25.3K	0.03%	307

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State of Wyoming's ADCT Position: Q2 2026 in Review

State of Wyoming increased its ADC Therapeutics (ADCT) stake by 181% in Q2 2026, buying an estimated $10.7K and bringing the position to 5,713 shares worth $6.11K. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

State of Wyoming first reported a position in ADCT in Q1 2021 and has held it in 9 quarters since. The position peaked at $57K in Q2 2021. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

State of Wyoming held 5,713 shares of ADC Therapeutics worth $6.11K as of Q2 2026.
State of Wyoming bought 3,681 ADC Therapeutics shares in Q2 2026, an estimated $10.7K.
ADC Therapeutics made up ﹤0.01% of State of Wyoming's portfolio in Q2 2026, its #1845 holding.
State of Wyoming first reported a position in ADC Therapeutics in Q1 2021 and has held it in 9 quarters since.
State of Wyoming's ADC Therapeutics position peaked at $57K in Q2 2021.
113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.